Prelude Therapeutics Files 8-K: Officer/Director Changes & Financials
Ticker: PRLD · Form: 8-K · Filed: Feb 5, 2025 · CIK: 1678660
Sentiment: neutral
Topics: management-change, corporate-governance, filing
Related Tickers: PRLD
TL;DR
Prelude Therapeutics (PRLD) filed an 8-K for officer/director changes and financials. Watch for leadership impact.
AI Summary
On February 3, 2025, Prelude Therapeutics Incorporated filed an 8-K report detailing the departure of certain officers and directors, the election of new directors, and updates to compensatory arrangements. The filing also includes financial statements and exhibits, with the report being filed as of February 5, 2025.
Why It Matters
This filing indicates potential shifts in the company's leadership and governance structure, which could impact strategic direction and investor confidence.
Risk Assessment
Risk Level: medium — Changes in directors and officers, along with compensatory arrangements, can signal internal shifts that may affect company strategy and performance.
Key Numbers
- 001-39527 — SEC File Number (Identifies the company's filing with the SEC.)
- 81-1384762 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- Prelude Therapeutics Incorporated (company) — Registrant
- February 3, 2025 (date) — Date of earliest event reported
- February 5, 2025 (date) — Date filing was made
- Delaware (location) — State of incorporation
- 175 Innovation Boulevard Wilmington, Delaware 19805 (address) — Principal executive offices
FAQ
Who are the specific officers and directors departing from Prelude Therapeutics?
The filing does not specify the names of the departing officers or directors in the provided text.
Who are the newly elected directors?
The filing mentions the election of directors but does not list their names in the provided text.
What are the details of the updated compensatory arrangements for officers?
The filing indicates updates to compensatory arrangements but does not provide specific details in the provided text.
What specific financial statements are included in this filing?
The filing states that financial statements and exhibits are included, but the specific statements are not detailed in the provided text.
What is the significance of the 'Date as of Change' being 20250205?
This date, February 5, 2025, is the date the report was filed with the SEC, indicating when the information became public.
Filing Stats: 1,070 words · 4 min read · ~4 pages · Grade level 12.5 · Accepted 2025-02-05 16:28:09
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share PRLD Nasdaq Glo
- $483,000 — ensation terms: a base annual salary of $483,000 (the "Base Salary") and eligibility for
Filing Documents
- prld-20250203.htm (8-K) — 58KB
- 0000950170-25-014543.txt ( ) — 203KB
- prld-20250203.xsd (EX-101.SCH) — 49KB
- prld-20250203_htm.xml (XML) — 5KB
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 104 Cover Page Interactive Data File (embedded within the Inline XBRL Document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. PRELUDE THERAPEUTICS INCORPORATED Date: February 5, 2025 By: /s/ Krishna Vaddi Krishna Vaddi, Ph.D. Chief Executive Officer